tetano
Editor, Senior Moderator
Cureus
. 2022 Oct 13;14(10):e30269.
doi: 10.7759/cureus.30269. eCollection 2022 Oct.
Complete, Rapid Resolution of Severe Bilateral Pneumonia and Acute Respiratory Distress Syndrome in a COVID-19 Patient: Role for a Unique Therapeutic Combination of Inhalations With Bromhexine, Higher Doses of Colchicine, and Hymecromone
Tsanko Mondeshki[SUP] 1 [/SUP], Radoslav Bilyukov[SUP] 1 [/SUP], Toma Tomov[SUP] 2 [/SUP], Miroslav Mihaylov[SUP] 3 [/SUP], Vanyo Mitev[SUP] 4 [/SUP]
Affiliations
Abstract
An otherwise healthy, 35-year-old man was hospitalized for the management of acute respiratory failure due to coronavirus disease 2019 (COVID-19)-related severe bilateral pneumonia and acute respiratory distress syndrome (ARDS). The patient therapeutic regimen included the widely accepted standard combination of oxygen, anticoagulation therapy; corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and antibiotics. A novel combination of colchicine, hymecromone, and bromhexine inhalations was added to the therapeutic regimen as part of our unique COVID-19 management institutional protocol. COVID-19-related severe bilateral pneumonia and acute respiratory distress syndrome (ARDS). The patient therapeutic regimen included the widely accepted standard combination of oxygen, anticoagulation therapy, corticosteroids, NSAIDs, and antibiotics. A novel combination of colchicine, hymecromone, and bromhexine inhalations was added to the therapeutic regimen as part of our unique COVID-19 management institutional protocol. Rapid clinical response on day 2, with a significant improvement of radiographic pulmonary changes on day 5, and improvement of laboratory results on days 5-7 were observed. The administration of inhalatory bromhexine in combination with high-dose colchicine and hymecromone was crucial for the positive outcome of the disease. This treatment regimen resulted in a four to five-fold decrease in the mortality of hospitalized patients.
Keywords: bradykinin storm; bromhexine; colchicine; covid-19; cytokine storm; hyaluronan storm; hymecromone; nlrp3 inflammasome.
. 2022 Oct 13;14(10):e30269.
doi: 10.7759/cureus.30269. eCollection 2022 Oct.
Complete, Rapid Resolution of Severe Bilateral Pneumonia and Acute Respiratory Distress Syndrome in a COVID-19 Patient: Role for a Unique Therapeutic Combination of Inhalations With Bromhexine, Higher Doses of Colchicine, and Hymecromone
Tsanko Mondeshki[SUP] 1 [/SUP], Radoslav Bilyukov[SUP] 1 [/SUP], Toma Tomov[SUP] 2 [/SUP], Miroslav Mihaylov[SUP] 3 [/SUP], Vanyo Mitev[SUP] 4 [/SUP]
Affiliations
- PMID: 36381705
- PMCID: PMC9653175
- DOI: 10.7759/cureus.30269
Abstract
An otherwise healthy, 35-year-old man was hospitalized for the management of acute respiratory failure due to coronavirus disease 2019 (COVID-19)-related severe bilateral pneumonia and acute respiratory distress syndrome (ARDS). The patient therapeutic regimen included the widely accepted standard combination of oxygen, anticoagulation therapy; corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and antibiotics. A novel combination of colchicine, hymecromone, and bromhexine inhalations was added to the therapeutic regimen as part of our unique COVID-19 management institutional protocol. COVID-19-related severe bilateral pneumonia and acute respiratory distress syndrome (ARDS). The patient therapeutic regimen included the widely accepted standard combination of oxygen, anticoagulation therapy, corticosteroids, NSAIDs, and antibiotics. A novel combination of colchicine, hymecromone, and bromhexine inhalations was added to the therapeutic regimen as part of our unique COVID-19 management institutional protocol. Rapid clinical response on day 2, with a significant improvement of radiographic pulmonary changes on day 5, and improvement of laboratory results on days 5-7 were observed. The administration of inhalatory bromhexine in combination with high-dose colchicine and hymecromone was crucial for the positive outcome of the disease. This treatment regimen resulted in a four to five-fold decrease in the mortality of hospitalized patients.
Keywords: bradykinin storm; bromhexine; colchicine; covid-19; cytokine storm; hyaluronan storm; hymecromone; nlrp3 inflammasome.